CA2386955A1 - Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline - Google Patents

Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline Download PDF

Info

Publication number
CA2386955A1
CA2386955A1 CA002386955A CA2386955A CA2386955A1 CA 2386955 A1 CA2386955 A1 CA 2386955A1 CA 002386955 A CA002386955 A CA 002386955A CA 2386955 A CA2386955 A CA 2386955A CA 2386955 A1 CA2386955 A1 CA 2386955A1
Authority
CA
Canada
Prior art keywords
quinazolin
phenyl
cyclopentyl
piperazin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386955A
Other languages
English (en)
Inventor
Mark Robert Barvian
Yadagiri Bathini
Ellen Myra Dobrusin
James Stanley Kaltenbronn
Ronald George Micetich
Inderjit S. Sidhu
Rajeshwar Singh
Peter Laurence Toogood
Roy Thomas Winters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386955A1 publication Critical patent/CA2386955A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte sur des quinazolines qui sont utiles pour traiter des pathologies et états induisant la prolifération cellulaire tels que les maladies cardio-vasculaires, les infections, les cancers, les maladies auto-immunes, la goutte, les maladies du foie et les maladies et états dégénératifs tels que la maladie d'Alzheimer. Nous avons maintenant découvert un groupe de 2-arylamino- quinazolines (I) et (II) qui sont de puissants inhibiteurs des kinases dépendant de la cycline (cdks). Les composés sont facilement synthétisés et peuvent être administrés de différentes manières, y compris par voie orale, et ont une biodisponibilité suffisante. Cette invention porte également sur des formulations pharmaceutiques comprenant au moins un des composés de quinazoline et un support acceptable d'un point de vue pharmaceutique, un diluant ou un excipient de celui-ci. L'invention porte en outre sur des intermédiaires utiles générés au cours de la production des composés de quinalozine.
CA002386955A 1999-11-22 2000-11-03 Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline Abandoned CA2386955A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16684099P 1999-11-22 1999-11-22
US60/166,840 1999-11-22
PCT/US2000/030376 WO2001038315A1 (fr) 1999-11-22 2000-11-03 Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline

Publications (1)

Publication Number Publication Date
CA2386955A1 true CA2386955A1 (fr) 2001-05-31

Family

ID=22604900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386955A Abandoned CA2386955A1 (fr) 1999-11-22 2000-11-03 Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline

Country Status (7)

Country Link
EP (1) EP1235815A1 (fr)
JP (1) JP2003514901A (fr)
AU (1) AU1462101A (fr)
BR (1) BR0015718A (fr)
CA (1) CA2386955A1 (fr)
MX (1) MXPA02003140A (fr)
WO (1) WO2001038315A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
KR20060006037A (ko) 2003-04-16 2006-01-18 에프. 호프만-라 로슈 아게 류머티스성 관절염과 같은 염증성 질병의 치료를 위한 ｐ38 키나아제 저해제로서의 (6-(페녹시)-피리도[3,4-ｄ]피리미딘-2-일)-아민 유도체
BRPI0409580A (pt) * 2003-04-16 2006-04-18 Hoffmann La Roche compostos de quinazolina
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006017844A1 (fr) 2004-08-06 2006-02-16 Janssen Pharmaceutica, N.V. Nouveaux derives de 2-amino-quinazoline utiles en tant qu'inhibiteurs de la $g(b)-secretase (bace)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006118256A1 (fr) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Dérivés de 2-aminoquinazoline
EP1917245A1 (fr) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Composes heterocycliques et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092839A2 (fr) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. DÉRIVÉS MACROCYCLIQUES UTILES COMME INHIBITEURS DE LA β-SÉCRÉTASE (BACE)
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2008050808A1 (fr) * 2006-10-24 2008-05-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
ES2400173T3 (es) 2008-01-28 2013-04-08 Janssen Pharmaceutica Nv Derivados de 6-sustituido-tio-2-amino-quinolina útiles como inhibidores de beta-secretasa (BACE)
MX2010008243A (es) 2008-01-29 2010-11-30 Janssen Pharmaceutica Nv Derivados de 2-aminoquinolina utiles como inhibidores de beta-secretasa (bace).
CA2719538C (fr) 2008-04-07 2014-03-18 Amgen Inc. Pyridines/pyrimidines amino spirocycliques et disubstituees par gem en tant qu'inhibiteurs de cycle cellulaire
KR20100134693A (ko) 2008-04-23 2010-12-23 교와 핫꼬 기린 가부시키가이샤 2-아미노퀴나졸린 유도체
MA32968B1 (fr) * 2008-12-29 2012-01-02 Fovea Pharmaceuticals Composes quinazoline substitues
CA2751517A1 (fr) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines servant d'inhibiteurs de kinases
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
WO2014011900A2 (fr) 2012-07-11 2014-01-16 Blueprint Medicines Inhibiteurs du récepteur du facteur de croissance de fibroblastes
EP3060560A1 (fr) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibiteurs du récepteur du facteur de croissance des fibroblastes
JP6483697B2 (ja) * 2013-12-09 2019-03-13 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体
WO2015108992A1 (fr) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4
MX2017008520A (es) 2014-12-24 2018-03-01 Gilead Sciences Inc Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
PT3237397T (pt) 2014-12-24 2019-02-08 Gilead Sciences Inc Compostos de isoquinolina para o tratamento de hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
CN112661750B (zh) * 2020-12-29 2022-10-21 西南大学 烯酮桥联的喹唑酮噻唑类化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
CA1307786C (fr) * 1984-12-14 1992-09-22 Keiichi Yokoyama Derives quinazoline et preparations antihypertension contenant les memescomposes comme ingredients actifs
EP0964864B1 (fr) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3d pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire

Also Published As

Publication number Publication date
WO2001038315A1 (fr) 2001-05-31
AU1462101A (en) 2001-06-04
EP1235815A1 (fr) 2002-09-04
JP2003514901A (ja) 2003-04-22
MXPA02003140A (es) 2002-09-30
BR0015718A (pt) 2002-07-23

Similar Documents

Publication Publication Date Title
CA2386955A1 (fr) Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
CA2329703C (fr) Pyrimidines bicycliques et 3,4-dihydropyrimidines bicycliques, inhibiteurs de proliferation cellulaire
US7576091B2 (en) Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
US7781583B2 (en) Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones
CA2592723A1 (fr) Derives de 4-(1h-indol-3-yl)-pyrimidin-2-ylamine et leur utilisation a des fins therapeutiques
US20030130286A1 (en) Pteridinones as kinase inhibitors
EP1401831A1 (fr) Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase
JPH11504922A (ja) 蛋白チロシンキナーゼ媒介細胞増殖を抑制するためのピリド［２，３−ｄ］ピリミジン類
US20040044012A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
SK10772002A3 (sk) Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
JP2007500178A (ja) プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
WO2003068754A1 (fr) Derives d'indazole therapeutiques a substitution
US6683183B2 (en) Pyridotriazines and pyridopyridazines
WO2004067000A1 (fr) Oxydes de benzothiazole-3 utiles pour le traitement de troubles proliferatifs
US6982260B1 (en) Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US7026313B2 (en) 2-thia-1,6,8-triaza-naphthalene-2,2-dioxides are kinase inhibitors
Jain Design and synthesis of novel benzimidazoles and aminothiazoles as small molecule inhibitors of CDK5/p25
EP1801112A1 (fr) Pyrimidines bicycliques et dihydropyrimidines 3,4 bicyliques en tant qu'inhibiteurs de prolifération cellulaire

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead